Shozo Matsuoka - Ono Pharmaceutical Executive
| OPHLF Stock | USD 11.19 0.00 0.00% |
Executive
Mr. Shozo Matsuoka was serving as Executive Officer and Director of NV Strategy Planning in ONO PHARMACEUTICAL CO., LTD. since 2017. He joined the Company in April 1985. His previous titles include Chief Director of Development, Director of Business Planning, Managing Director, Chief Director of Business Strategy and Senior Managing Director in the Company. since 2017.
| Age | 58 |
| Tenure | 8 years |
| Phone | 81 6 6263 5670 |
| Web | https://www.ono-pharma.com |
Ono Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1204 % which means that it generated a profit of $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1605 %, meaning that it generated $0.1605 on every $100 dollars invested by stockholders. Ono Pharmaceutical's management efficiency ratios could be used to measure how well Ono Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Charlotte PamerWieser | Novartis AG ADR | N/A | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Linda MD | Novartis AG ADR | 61 | |
| Johanna Mercier | Gilead Sciences | 55 | |
| Steffen Lang | Novartis AG ADR | 58 | |
| Roy Papatheodorou | Sanofi ADR | 47 | |
| Ahn Poole | Bristol Myers Squibb | 50 | |
| Flavius MD | Gilead Sciences | N/A | |
| Thomas Larsen | Sanofi ADR | 51 | |
| Aharon Gal | Novartis AG ADR | N/A | |
| Rudolf Ertl | Gilead Sciences | 79 | |
| Sloan Simpson | Novartis AG ADR | N/A | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Karin Shanahan | Bristol Myers Squibb | 60 | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Steven Baert | Novartis AG ADR | 45 | |
| Kimberly Jablonski | Bristol Myers Squibb | N/A | |
| Joseph Eiden | Bristol Myers Squibb | 76 | |
| Adam Lenkowsky | Bristol Myers Squibb | 53 | |
| Bilal Piperdi | Gilead Sciences | N/A | |
| Monica Tijerina | Gilead Sciences | N/A | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 |
Ono Pharmaceutical Leadership Team
Elected by the shareholders, the Ono Pharmaceutical's board of directors comprises two types of representatives: Ono Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ono. The board's role is to monitor Ono Pharmaceutical's management team and ensure that shareholders' interests are well served. Ono Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ono Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gyo Sagara, CEO and President and Representative Director | ||
| Hiromu Habashita, Executive Officer, Chief Director of Research | ||
| Katsuji Teranishi, Head of Marketing Strategy Planning, Deputy Director of Sales and Marketingl and Corporate Officer | ||
| Toshihiro Tsujinaka, Executive Officer, Senior Director of Oncology in Main Sales Unit | ||
| Shozo Matsuoka, Executive Officer, Manager of R & D Strategy Office | ||
| Kiyoaki Idemitsu, Exec Officer | ||
| Hiroshi Ichikawa, Sr. Director of Metropolitan Area Management and Metropolitan Area First Branch and Corporate Officer | ||
| Isao Ono, Executive Officer, Manager of Environmental Management Office, Director | ||
| Yukio Tani, Executive Officer, Director of Public Relations | ||
| Toichi Takino, Executive Director of Corporate Devel. and Strategy and Corporate Officer |
Ono Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ono Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 488.31 M | |||
| Shares Owned By Insiders | 16.04 % | |||
| Shares Owned By Institutions | 44.41 % | |||
| Price To Earning | 18.12 X | |||
| Price To Book | 2.29 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.